Mark W Ball1, Michael A Gorin2, Sam B Bhayani3, Craig G Rogers4, Michael D Stifelman5, Jihad H Kaouk6, Homayoun Zargar6, Susan Marshall5, Jeffrey A Larson3, Haider M Rahbar4, Bruce J Trock2, Phillip M Pierorazio2, Mohamad E Allaf2. 1. The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: mark.ball@jhmi.edu. 2. The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD. 3. Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO. 4. Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. 5. Department of Urology, New York University, Langone Medical Center, New York, NY. 6. Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Abstract
PURPOSE: To determine preoperative predictors associated with renal cell carcinoma (RCC) and unfavorable pathology in small renal masses treated with partial nephrectomy (PN). MATERIALS AND METHODS: PN records from 5 centers were retrospectively queried for patients with a clinically localized single tumor <4 cm on imaging (clinical T1a). Between 2007 and 2013, 1,009 patients met the inclusion criteria. Unfavorable pathology was defined as any grade III or IV RCC or tumors upstaged to pathologic T3a disease. Logistic regression models were used to determine preoperative characteristics associated with RCC and with unfavorable pathology. RESULTS: A total of 771 (76.4%) patients were found to have RCC and 198 (19.6%) had unfavorable pathology. On multivariate, bootstrap-adjusted logistic regression analysis, factors associated with the presence of malignancy were imaging tumor size ≥ 3 cm (odds ratio [OR] = 1.46; P = 0.040), male sex (OR = 1.88; P<0.0001), and nephrometry score ≥ 8 (OR = 1.64; P = 0.005). These same factors were independently associated with risk of unfavorable pathology: size ≥ 3 cm (OR = 1.46; P = 0.021), male sex (OR = 2.35; P<0.0001), and nephrometry score ≥ 8 (OR = 1.49; P = 0.015). The c statistic was 0.62 for the predicting malignancy and 0.63 for unfavorable pathology. CONCLUSIONS: In this multi-institutional cohort, male sex, imaging tumor size ≥ 3 cm, and nephrometry score ≥ 8 were predictors of RCC and adverse pathology following PN. These factors may assist in risk stratification and selective renal mass biopsy before decision making. Further studies are necessary to validate these findings.
PURPOSE: To determine preoperative predictors associated with renal cell carcinoma (RCC) and unfavorable pathology in small renal masses treated with partial nephrectomy (PN). MATERIALS AND METHODS: PN records from 5 centers were retrospectively queried for patients with a clinically localized single tumor <4 cm on imaging (clinical T1a). Between 2007 and 2013, 1,009 patients met the inclusion criteria. Unfavorable pathology was defined as any grade III or IV RCC or tumors upstaged to pathologic T3a disease. Logistic regression models were used to determine preoperative characteristics associated with RCC and with unfavorable pathology. RESULTS: A total of 771 (76.4%) patients were found to have RCC and 198 (19.6%) had unfavorable pathology. On multivariate, bootstrap-adjusted logistic regression analysis, factors associated with the presence of malignancy were imaging tumor size ≥ 3 cm (odds ratio [OR] = 1.46; P = 0.040), male sex (OR = 1.88; P<0.0001), and nephrometry score ≥ 8 (OR = 1.64; P = 0.005). These same factors were independently associated with risk of unfavorable pathology: size ≥ 3 cm (OR = 1.46; P = 0.021), male sex (OR = 2.35; P<0.0001), and nephrometry score ≥ 8 (OR = 1.49; P = 0.015). The c statistic was 0.62 for the predicting malignancy and 0.63 for unfavorable pathology. CONCLUSIONS: In this multi-institutional cohort, male sex, imaging tumor size ≥ 3 cm, and nephrometry score ≥ 8 were predictors of RCC and adverse pathology following PN. These factors may assist in risk stratification and selective renal mass biopsy before decision making. Further studies are necessary to validate these findings.
Authors: Alessandro Antonelli; Maria Furlan; Marco Sandri; Andrea Minervini; Luca Cindolo; Paolo Parma; Stefano Zaramella; Angelo Porreca; Gianni Vittori; Alessandro Samuelli; Donato Dente; Francesco Berardinelli; Maria Rosaria Raspollini; Sergio Serni; Marco Carini; Carlo Terrone; Luigi Schips; Claudio Simeone Journal: Clin Genitourin Cancer Date: 2014-02-21 Impact factor: 2.872
Authors: Alessandro Volpe; Antonio Finelli; Inderbir S Gill; Michael A S Jewett; Guido Martignoni; Thomas J Polascik; Mesut Remzi; Robert G Uzzo Journal: Eur Urol Date: 2012-05-12 Impact factor: 20.096
Authors: Mark W Ball; Stephania M Bezerra; Michael A Gorin; Morgan Cowan; Christian P Pavlovich; Phillip M Pierorazio; George J Netto; Mohamad E Allaf Journal: J Urol Date: 2014-06-21 Impact factor: 7.450
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2003-12 Impact factor: 7.450
Authors: L Cindolo; A de la Taille; G Messina; L Romis; C C Abbou; V Altieri; A Rodriguez; J J Patard Journal: BJU Int Date: 2003-12 Impact factor: 5.588
Authors: John B Eifler; Zhaoyang Feng; Brian M Lin; Michael T Partin; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Patrick C Walsh; Bruce J Trock; Alan W Partin Journal: BJU Int Date: 2012-07-26 Impact factor: 5.588
Authors: Michael A Gorin; Mark W Ball; Phillip M Pierorazio; Youssef S Tanagho; Sam B Bhayani; Jihad H Kaouk; Craig G Rogers; Michael D Stifelman; Ali Khalifeh; Ramesh Kumar; Ganesh Sivarajan; Mohamad E Allaf Journal: J Urol Date: 2013-06-11 Impact factor: 7.450
Authors: Jeffrey K Mullins; Jihad H Kaouk; Sam Bhayani; Craig G Rogers; Michael D Stifelman; Phillip M Pierorazio; Youssef S Tanagho; Shahab P Hillyer; Bartosz F Kaczmarek; Yichun Chiu; Mohamad E Allaf Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: Julie Y An; Mark W Ball; Michael A Gorin; Jiwon J Hong; Michael H Johnson; Christian P Pavlovich; Mohamad E Allaf; Phillip M Pierorazio Journal: Urology Date: 2016-11-23 Impact factor: 2.649
Authors: Hiten D Patel; Emmanuel Iyoha; Phillip M Pierorazio; Stephen M Sozio; Michael H Johnson; Ritu Sharma; Eric B Bass; Mohamad E Allaf Journal: Urology Date: 2016-08-16 Impact factor: 2.649
Authors: Thiago Camelo Mourão; Diego Abreu; Gustavo F Carvalhal; Guillermo Gueglio; Walter H da Costa; Vinicius Fernando Calsavara; Luis Meza-Montoya; Rubén G Bengió; Carlos Scorticati; Ricardo Castillejos-Molina; Francisco Rodríguez-Covarrubias; Ana María Autran-Gómez; José Gadu Campos-Salcedo; Alejandro Nolazco; Carlos Ameri; Hamilton Zampolli; Raúl Langenhin; Diego Muguruza; Marcos Tobias Machado; Pablo Mingote; Jorge Clavijo; Lucas Nogueira; Omar Clark; Agustín R Rovegno; Fernando P Secin; Ricardo Decia; Gustavo C Guimarães; Sidney Glina; Oscar Rodríguez-Faba; Joan Palou; Stenio C Zequi Journal: BMC Urol Date: 2020-07-02 Impact factor: 2.264
Authors: B Reix; J-C Bernhard; J-J Patard; P Bigot; A Villers; E Suer; N S Vuong; G Verhoest; Q Alimi; J-B Beauval; T Benoit; F-X Nouhaud; C Lenormand; N Hamidi; J Cai; M Eto; S Larre; A El Bakhri; G Ploussard; A Hung; N Koutlidis; A Schneider; J Carrouget; S Droupy; S Marchal; A Doerfler; S Seddik; T Matsugasumi; X Orsoni; A Descazeaud; C Pfister; K Bensalah; M Soulie; I Gill; V Flamand Journal: Prog Urol Date: 2018-01-11 Impact factor: 1.090